Refractory Multiple News Today

Media contact: Investor contact: ...

In case you missed it, below is a recap of all drugs that have been approved by the FDA in February 2024.

Currently, the safety and efficacy of linvoseltamab in adult patients with relapsed or refractory multiple myeloma is being compared to elotuzumab, pomalidomide, and dexamethasone in a phase 3 clinical trial.

/PRNewswire/ -- Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application...

Experts discuss treatment in newly diagnosed multiple myeloma and the role of CAR T-cell therapies and bispecifics in relapsed/refractory disease.

This alliance brings together drug innovation capabilities of Ichnos and Glenmark to develop cutting-edge therapies for the treatment of hematological...

FibroBiologics Inc. (FBLG) plans to raise $0 in an initial public offering on Wednesday, January 31st, IPO Scoop reports. The company will issue 4,806,226 shares at a price of $0.00 per share. FibroBiologics (Direct Listing) provided the following description of their company for its IPO: “Note: This is NOT an IPO. This is a NASDAQ […]

Rafat Abonour, MD briefly summarizes the current treatment landscape for Relapsed/Refractory Multiple Myeloma (R/R MM) and discusses the diverse strategies and advancements in managing this complex disease.

Ajai Chari, MD, discusses the efficacy of treating patients with less frequent or lower intensity dosing of talquetamab in patients with relapsed/refractory multiple myeloma, as evaluated in the phase 1/2 MonumenTAL-1 study.

Jeffrey Matous, MD, discusses outcomes from the phase 1b MonumenTAL-2 trial with the combination of talquetamab and pomalidomide in patients with relapsed/refractory multiple myeloma.